Horw, Switzerland began a pilot commercial launch for the FDA-cleared and CE-marked device in early 2021. In April 2021, the company raised $115 million to support that launch and scale up manufacturing. Since then, it says it has helped patients avoid 10 million mealtime injections, reflecting its impact on simplifying diabetes management.
According to a news release, multiple daily injections (MDI) — often required for mealtime insulin — can disrupt routines, burden emotional and physical health and interfere with social and work life. On average, people on mealtime insulin require more than 1,000 injections each year, CeQur says. However, the company says 72% of patients report not taking insulin outside the home. Additionally, 57% admit to missing injections they knew they should take.
CeQur introduced Simplicity to change that, as the discreet, wearable patch eliminates the need for MDI. It makes it easier to dose anytime, anywhere.
Last year, the FDA granted 510(k) clearance for Simplicity for an extended wear duration. Clearance extended the wear time for the wearable mealtime insulin delivery patch from three to four days. It marks a significant advancement for what the company says is the longest wearable insulin delivery patch, which provides diabetes discretion, additional convenience and injection-free dosing.
CeQur announces commercial expansion, too
CeQur said that, to support continued growth and ensure more patients benefit from its technology, it expanded its commercial organization. That expansion includes the addition of top-tier sales leadership and growth within its clinical diabetes specialist team.
The company also closed a $120 million financing round to support its wearable insulin delivery technology at the start of 2025.
In March 2025, the company added Darin Row as VP of sales. Row has more than 20 years of diabetes-focused and product launch experience, including leadership posts at Lilly, Amylin and Dexcom.
Additionally, the company selected Janelle Duffee as its director of clinical education last year. Duffee has more than 25 years of diabetes experience, including leadership roles at Insulet. She has played “a key role” in expanding the company’s field-based clinical diabetes specialist team.
